CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...
Recursion ended Q2 2025 with $533M in cash, a 35% reduction in expected cash burn by 2026 versus 2024, and reaffirmed guidance for over $100M in partnership inflows by end of 2026. The company ...
Recursion reported a transformative quarter marked by its initial clinical proof of concept for FAP, a 35% YoY reduction in pro forma operating expenses, and $754 million in year-end cash. Management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results